Promacta Generic: When Will Generic Eltrombopag Olamine Be Available?

Promacta’s Road to a Generic

Promacta has had the market to itself since the FDA approved it in November 2008 (Novartis Pharmaceuticals Corp). Its one listed patent has expired. Generic companies have challenged its patents with the FDA since January 2014.

The first generic of Promacta is expected sometime in 2026.

2 generic makers have filed applications with FDA. What opens the door, a ruling, a deal or an expiry, is not settled yet.

Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.

Promacta Patents and FDA Protections

Every patent and exclusivity the FDA Orange Book lists for Promacta’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.

Source: FDA Orange Book, application 022291. Patent numbers open the patent on Google Patents.

Patent Challenges to Promacta

The first patent challenge to Promacta reached the FDA in January 2014, from one company on that first day. The FDA’s list has 3 entries for Promacta, by form and strength. A first challenger began selling its generic in May 2025.

Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.

Who Is Lined Up to Make Generic Eltrombopag Olamine

Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.

Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).

Promacta Price: What Pharmacies Pay and What Generics Usually Do

What Medicare and Medicaid Spend on Promacta

Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.

Promacta Strengths and Forms

Source: FDA Orange Book, Novartis Pharmaceuticals Corp. Listed for sale today by Novartis Pharmaceuticals Corporation (FDA NDC Directory).

Promacta NDC Codes and Packages

Each Promacta package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.

Source: the FDA NDC Directory, current listings only. Only packages sold under Promacta’s own FDA approval (NDA 22291) are listed, never a generic. Some codes belong to companies that repackage Promacta: it is the same medicine in a different package.

Changes to This Projection

• October 2026First generic expected Sometime in 2026 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.

Every change to the expected month is logged here with the month we saw it.